52.92
1.05 (2.01%)
| Penutupan Terdahulu | 51.87 |
| Buka | 51.25 |
| Jumlah Dagangan | 140,736 |
| Purata Dagangan (3B) | 735,391 |
| Modal Pasaran | 2,287,149,824 |
| Harga / Jualan (P/S) | 1.77 |
| Harga / Buku (P/B) | 10.29 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 10 Mar 2026 |
| Margin Operasi (TTM) | -2,852.71% |
| EPS Cair (TTM) | -2.83 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 33.10% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.43% |
| Nisbah Semasa (MRQ) | 15.98 |
| Aliran Tunai Operasi (OCF TTM) | -90.87 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -52.44 M |
| Pulangan Atas Aset (ROA TTM) | -20.04% |
| Pulangan Atas Ekuiti (ROE TTM) | -28.73% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Dianthus Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 0.20 |
|
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 7.87% |
| % Dimiliki oleh Institusi | 119.90% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 200.00 (Guggenheim, 277.97%) | Beli |
| Median | 130.00 (145.68%) | |
| Rendah | 81.00 (Jefferies, 53.08%) | Beli |
| Purata | 128.22 (142.31%) | |
| Jumlah | 9 Beli | |
| Harga Purata @ Panggilan | 77.11 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Wedbush | 12 Mar 2026 | 103.00 (94.65%) | Beli | 80.32 |
| 10 Mar 2026 | 80.00 (51.19%) | Beli | 86.92 | |
| Baird | 10 Mar 2026 | 132.00 (149.46%) | Beli | 86.92 |
| Clear Street | 10 Mar 2026 | 130.00 (145.68%) | Beli | 86.92 |
| Raymond James | 10 Mar 2026 | 123.00 (132.45%) | Beli | 86.92 |
| HC Wainwright & Co. | 09 Mar 2026 | 130.00 (145.68%) | Beli | 79.23 |
| Oppenheimer | 09 Mar 2026 | 145.00 (174.02%) | Beli | 79.23 |
| Truist Securities | 09 Mar 2026 | 110.00 (107.88%) | Beli | 79.23 |
| Guggenheim | 04 Mar 2026 | 200.00 (277.96%) | Beli | 62.03 |
| Jefferies | 02 Feb 2026 | 81.00 (53.08%) | Beli | 53.18 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| SAVITZ RYAN | - | 91.66 | -8,224 | -753,812 |
| Jumlah Keseluruhan Kuantiti Bersih | -8,224 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -753,812 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 91.66 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| SAVITZ RYAN | Pegawai | 09 Apr 2026 | Jual automatik (-) | 8,224 | 91.66 | 753,812 |
| SAVITZ RYAN | Pegawai | 09 Apr 2026 | Pelaksanaan pilihan | 8,224 | - | - |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 05 Feb 2026 | Pengumuman | Dianthus Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |